Results 71 to 80 of about 86,485 (257)
Arthritis Care &Research, EarlyView.Objective Despite guideline recommendations, long‐term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. Methods Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis Registry were surveyed ...
Michael D. George +7 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective Systemic sclerosis (SSc) is characterized by cardiovascular risk excess not fully explained by traditional factors. Whether the severity of microvascular damage correlates with structural subclinical atherosclerosis remains unclear. We investigated the relationship between nailfold videocapillaroscopy (NVC) abnormalities and carotid ...
Eugenio Capparelli +13 more
wiley +1 more source
Rheumatology and Therapy, 2018 Introduction This study was conducted to observe patterns of use of the interleukin-6 receptor-alpha inhibitor tocilizumab in routine clinical practice in patients with rheumatoid arthritis (RA).
Boulos Haraoui +5 more
doaj +1 more source
Scientific Reports, 2023 Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19.
Neven Mohamed Sarhan +4 more
doaj +1 more source
Tocilizumab: From rheumatic diseases to covid-19
, 2021 Tocilizumab is a humanised interleukin-6 receptor-inhibiting monoclonal antibody that is currently approved for the treatment of rheumatoid arthritis and other immune-related conditions. Recently, tocilizumab has been investigated as a possible treatment
Tovoli F. +3 more
core +1 more source
Arthritis Care &Research, Accepted Article.Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi +10 more
wiley +1 more source
Arthritis Care &Research, Accepted Article.Objective To characterize the prevalence and correlates of dietary supplement use, identify commonly used supplements, and evaluate potential supplement–medication interactions among adults with systemic lupus erythematosus (SLE). Methods We analyzed cross‐sectional data from 451 adults in the Approaches to Positive, Patient‐centered Experiences of ...
Sarah L. Patterson +7 more
wiley +1 more source
Acute appendicitis in a rheumatoid arthritis patient treated with tocilizumab: report of a case
, 2015 A 55-year-old woman had been treated for rheumatoid arthritis with tocilizumab 1 month prior to the onset of mild abdominal pain. Computed tomography revealed swelling of the appendix and ascites around the appendix.
Koga, Naoki +6 more
core
Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab [PDF]
, 2017 HS628 has been developed as a proposed biosimilar product of originator tocilizumab (Actemra®). An extensive physicochemical and biological characterization was conducted to assess similarity between HS628 and originator tocilizumab.
Shiwei Miao +6 more
core +1 more source
Arthritis Care &Research, Accepted Article.Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in giant cell arteritis (GCA) patients. Methods This multicentre retrospective study included patients with GCA who received secukinumab at 14 Italian centres with at least 6 months of follow‐up.
Luca Iorio +29 more
wiley +1 more source